TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
8.70
-0.26 (-2.90%)
At close: Apr 7, 2026, 4:00 PM EDT
8.66
-0.04 (-0.46%)
After-hours: Apr 7, 2026, 6:22 PM EDT
TransCode Therapeutics Employees
TransCode Therapeutics had 7 employees as of December 31, 2024. The number of employees decreased by 3 or -30.00% compared to the previous year.
Employees
7
Change
-3
Growth
-30.00%
Revenue / Employee
n/a
Profits / Employee
-$3,876,275
Market Cap
7.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 7 | -3 | -30.00% | 7 | 0 |
| Sep 30, 2024 | 8 | -2 | -20.00% | 8 | 0 |
| Dec 31, 2023 | 10 | -9 | -47.37% | 10 | 0 |
| Dec 31, 2022 | 19 | 10 | 111.11% | 19 | 0 |
| Dec 31, 2021 | 9 | 3 | 50.00% | 8 | 1 |
| Sep 30, 2021 | 7 | 1 | 16.67% | 7 | 0 |
| Jun 30, 2021 | 6 | 0 | - | 2 | 4 |
| Mar 31, 2021 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2020 | 6 | 0 | - | 2 | 4 |
| Sep 30, 2020 | 6 | 0 | - | 2 | 4 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Employee RankingsRNAZ News
- 19 hours ago - TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028 - PRNewsWire
- 5 weeks ago - TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients - PRNewsWire
- 6 weeks ago - TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development - PRNewsWire
- 2 months ago - TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 - PRNewsWire
- 3 months ago - TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma - PRNewsWire
- 3 months ago - TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors - PRNewsWire
- 4 months ago - TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial - PRNewsWire
- 5 months ago - TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer - PRNewsWire